Merus N.V., a biotechnology firm specializing in oncology, has announced a proposed underwritten public offering of its common shares. All shares in this offering will be provided by Merus, with an additional option for underwriters to purchase up to 15% more shares. The company plans to use the proceeds to further the clinical development of its product candidates and for general corporate purposes. The offering, managed by Jefferies, BofA Securities, Leerink Partners, and others, is contingent on market and closing conditions. A preliminary prospectus supplement will be available on the SEC's website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。